Current Views On The Pathogenesis Of The Parietal-Visceral Pathway Of Gastric Cancer Metastasis

Metastases to the peritoneum occur in 55-60% of patients with gastric cancer and are associated with a 5-year overall survival of 2%. Treatment options for these patients are limited, and targeted therapy or immunotherapy is not available. Rational therapeutic targets have yet to be found.In this review, we present the published literature and our own recent experience in molecular biology to identify important molecules and signalling pathways as well as cellular immunity involved in GC peritoneal metastases.